# OnCo record paper-olympia-overall-survival-ann-oncol-2022 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: .
@prefix onco: .
@prefix xsd: .
a schema:ScholarlyArticle ;
onco:kind "paper" ;
schema:identifier "paper-olympia-overall-survival-ann-oncol-2022" ;
schema:name "Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer"@en ;
schema:description "The second planned analysis of OlympiA, at 3.5 years, in which a year of olaparib tablets after standard treatment cut deaths by 32 percent in women with an inherited BRCA fault, the first time a PARP inhibitor had lengthened life in early breast cancer."@en ;
schema:url ;
schema:dateModified "2026-09-24"^^xsd:date ;
schema:citation , , ;
onco:tag "tnbc-evidence" ;
schema:sameAs ;
schema:datePublished "2022"^^xsd:gYear ;
schema:author "Geyer CE, Garber JE, Gelber RD, et al." ;
onco:related , ;
onco:cancers , ;
onco:technologies , ;
onco:targets ;
onco:drugs ;
onco:companies , ;
onco:terms , , ;
onco:trials ;
onco:people , , ;
onco:journals .